← Back to headlines
Gilead Sciences Acquires Arcellx for $7.8 Billion
Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.
23 Feb, 11:30 — 23 Feb, 11:40
Moderate (27/100)
2 sourcesNarrow spread1 region
ℹAll sources from US region
ℹOnly 2 sources cover this story
Perspective Analysis
Comparing sources…
How outlets covered this
Left-leaning
No articles
Center
Right-leaning
No articles
Coverage Timeline
First report: seeking-alpha · 23 Feb, 11:30|Full coverage: All 2 sources within 10m|Window: 10m
Left-leaningCenterRight-leaning
Read at source (2 outlets)
cnbc2h ago
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Read full article →seeking-alpha3h ago
M&A Snapshot: Gilead acquires Arcellx for $7.8B
Read full article →Related Stories
Richmond Eduku: Unlike before, Central Bank’s financing of government’s deficit has been curtailed
3m ago
Western Asset Investment Grade Income Fund declares $0.0525 dividend
9m ago
Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says
9m ago
Jim Cramer's top 10 things to watch in the stock market Monday
9m ago